B · Normal
[Hengrui Pharmaceuticals: Subsidiary’s Class 1 new drug rifucibamab injection has been approved for marketing] On November 12, Hengrui Pharmaceutical (600276.SH) announced that the company’s subsidiary Beijing Shengdi Medicine received a notice from the State Food and Drug Administration approving the company’s independently developed Class 1 new drug rifucibamab injection for marketing. This medicine is indicated for the treatment of homozygous familial hypercholesterolemia in adults and adolescents 12 years of age and older to reduce low-density lipoprotein cholesterol levels. Up to now, the cumulative R&D investment in this drug-related project is approximately 303 million yuan.
Comments